Dear [NAME FIELD],

For more than 20 years, Bayer has been committed to answering the needs of the hemophilia A community.

Trusted support
Bayer is particularly dedicated to helping your patients maintain access to hemophilia A treatment. We know that changes resulting from healthcare reform can bring up concerns about securing and maintaining coverage. The Factor Solutions helpline provides live access to trained Case Specialists who offer one-on-one support as they help patients navigate difficult insurance issues. Spanish-speaking Case Specialists are also available.

Factor Solutions can also connect people with the Co-pay Assistance Program.
Enrollment is fast and simple; just instruct your patients to follow these steps:

	1.	Call Factor Solutions: A Case Specialist will help complete an application
	2.	Provide financial documentation to Patient Services, Inc. (PSI), which administers the program, when requested
	3.	Present the co-pay card to the pharmacy when ordering Kogenate^® FS, antihemophilic factor (recombinant)
Eligible members can be covered for up to $12,000 per year toward co-pay/co-insurance assistance, using a sliding scale based on income. You and your patient can connect with a Factor Solutions Case Specialist by calling 1-800-288-8374 between 8:30 AM to 5:30 PM (ET), or click here to explore what Factor Solutions has to offer your patients, and see a video introducing the program.

The Co-pay/Co-insurance Assistance Program: People with private, commercial health insurance may receive Kogenate^® FS co-pay or co-insurance assistance, based on eligibility requirements and income level. The program is on a first-come, first-served basis. Financial support is available for up to 12 months or until the program ends. The program is not for patients receiving prescription reimbursement under any federal-, state-, or government-funded insurance programs, or where prohibited by law. All people who meet these criteria are encouraged to apply.

Commitment to research
Bayer has also been a strong advocate of research, including studying the effects of prophylaxis treatment in children. We are proud of our successes in the field of research and are committed to research that can make a difference.

If you'd like to learn more about how Kogenate^® FS and Bayer can help your patients with hemophilia A, reach out to your Bayer HealthCare Representative.

INDICATIONS
Kogenate^® FS, antihemophilic factor (recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A.

Kogenate^® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

IMPORTANT SAFETY INFORMATION
Kogenate^® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to AHF.

The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

For important risk and use information, please see full Prescribing Information at http://www.factormatters.com/index.php/treatment/prescribing-information/.